• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Evercore ISI initiated coverage on SpringWorks Therapeutics with a new price target

    11/20/24 8:20:27 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SWTX alert in real time by email
    Evercore ISI initiated coverage of SpringWorks Therapeutics with a rating of Outperform and set a new price target of $60.00
    Get the next $SWTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SWTX

    DatePrice TargetRatingAnalyst
    11/20/2024$60.00Outperform
    Evercore ISI
    2/5/2024$75.00Buy
    Guggenheim
    12/1/2022$45.00Buy
    BofA Securities
    9/8/2021$97.00 → $105.00Overweight
    JP Morgan
    8/5/2021$136.00 → $137.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SWTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Edris Badreddin sold $1,084,592 worth of shares (20,000 units at $54.23), decreasing direct ownership by 11% to 169,712 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      3/5/25 6:33:49 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Islam Saqib covered exercise/tax liability with 30,756 shares and sold $2,657,656 worth of shares (49,000 units at $54.24), decreasing direct ownership by 8% to 954,869 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      3/5/25 6:32:29 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Islam Saqib sold $1,768,401 worth of shares (29,328 units at $60.30), decreasing direct ownership by 3% to 1,034,625 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      2/24/25 6:58:58 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

      – Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany's Healthcare business – – SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas – – Planned acquisition will strengthen the presence of Merck KGaA, Darmstadt, Germany's Healthcare business in

      4/28/25 2:13:33 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

      Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $3.9 billion Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for the Healthcare business of Merck KGaA, Darmstadt, Germany SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas Planned acquisition will strengthen the presence of the Healthcare business of Merck KGaA, Darmstadt, Germany, i

      4/28/25 2:11:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

      STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will adopt an opinion on the marketing authorization application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025. About SpringWorks Therapeutics SpringWorks is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases an

      4/27/25 10:35:13 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by SpringWorks Therapeutics Inc.

      10-Q - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      5/9/25 4:17:26 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by SpringWorks Therapeutics Inc.

      SCHEDULE 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      5/7/25 11:01:53 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by SpringWorks Therapeutics Inc.

      DEFA14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      4/28/25 4:02:03 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 27, 2023 - FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

      For Immediate Release: November 27, 2023 Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive. The tumor

      11/27/23 5:34:21 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for OGSIVEO issued to SPRINGWORKS THERAPEUTICS INC

      Submission status for SPRINGWORKS THERAPEUTICS INC's drug OGSIVEO (ORIG-1) with active ingredient NIROGACESTAT has changed to 'Approval' on 11/27/2023. Application Category: NDA, Application Number: 217677, Application Classification: Type 1 - New Molecular Entity

      11/27/23 5:34:04 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Financials

    Live finance-specific insights

    See more
    • SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

      – Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amendable to complete resection – – Ended 2024 with $461.9 million in cash, cash equivalents and marketable securities – STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the fourth quarter and full year periods ended December 31, 2024 and provi

      2/20/25 6:30:32 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

      STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcas

      1/30/25 7:00:50 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      – Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor symptoms, and consistent safety profile – – Granted FDA Priority Review on NDA and received validation of EU Marketing Authorization Application for mirdametinib for the treatment of adults and children with NF1-PN – – $498 million in cash, cash equivalents and marketable securities as of September 30, 2024; expected to fund the Company through profitability, which is anticipated in the first

      11/12/24 6:30:21 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc.

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      10/25/24 9:46:32 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      2/14/24 6:41:08 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      2/14/24 8:56:14 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on SpringWorks Therapeutics with a new price target

      Evercore ISI initiated coverage of SpringWorks Therapeutics with a rating of Outperform and set a new price target of $60.00

      11/20/24 8:20:27 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on SpringWorks Therapeutics with a new price target

      Guggenheim initiated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $75.00

      2/5/24 8:04:18 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities initiated coverage on SpringWorks Therapeutics with a new price target

      BofA Securities initiated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $45.00

      12/1/22 7:57:05 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Leadership Updates

    Live Leadership Updates

    See more
    • SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

      STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. "Martin is a proven industry leader whose experience in developing and delivering novel treatments to patients in need is exceptional," said Saqib Islam, Chief Executive Officer of SpringWorks. "His expertise

      7/29/24 6:30:11 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer

      STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer. Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. "Tai-An is a talented scientist with a strong track record of advancing innovative oncology programs from discovery

      9/11/23 6:30:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

      STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company's Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. ("AbbVie") until his retirement last year, brings over 30 years of experience in global commercial strategy and operations. "Carlos' success in building and leading global commercial organizations will be valuable as SpringWorks continues its planned transition into a commercial-stage compa

      7/15/22 6:30:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care